ADMA Biologics ADMA
$13.17 −$0.17 (-1.27%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.30 +0.99%
Open$13.26
Prev close$13.34
Day range$13.10 – $13.47
Volume2.45M
Market cap$2.92B
P/E (TTM)17.1
Dividend yield–
ADMA Stock News
Headlines matching ADMA Biologics or the ADMA ticker, most recent first.
- CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18
- Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Hold Rating, Cuts Target Price to $12 Negative
- ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate Negative
- 4: ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
- Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $17 Negative
- Raymond James Initiates ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $21
- Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $20 Negative
- CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $21
- ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
- Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $21 Negative
- Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $24 Negative
- Cantor Fitzgerald Downgrades ADMA Biologics(ADMA.US) to Hold Rating, Maintains Target Price $30 Negative
- ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Director Guiheen Lawrence P.
- ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
- Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $30
No comments yet — be the first to weigh in on ADMA.
Sign in to join the discussion.